Improving Workforce Planning in Pharmacy
Submitting Institution
King's College LondonUnit of Assessment
Business and Management StudiesSummary Impact Type
SocietalResearch Subject Area(s)
Medical and Health Sciences: Public Health and Health Services
Economics: Applied Economics
Summary of the impact
Research at King's has had a direct influence on the perceived value of
workforce planning in the
Department of Health and the Royal Pharmaceutical Society of Great Britain
(RPSGB) and has
resulted in its use in relation to pharmacists. Building on long-term
research, King's academics
developed a model to predict the demand for and supply of pharmacists in
the UK over a five and
ten year period. These findings changed thinking in the Department of
Health and the RPSGB in
2006, and underpinned a change in UK policy. A national policy decision
was taken to support the
opening and accreditation of up to eight new university Schools of
Pharmacy to help to address the
anticipated shortfall in the supply of pharmacists predicted by the
research.
Underpinning research
Building on long-term research on workforce patterns, King's staff were
commissioned by the
Department of Health through the Royal Pharmaceutical Society of Great
Britain (RPSGB) and an
ESRC Case Award in collaboration with the RPSGB between 2004-6 to develop
a workforce
planning model that could be used to identify the future supply of and
demand for pharmacists.
The director of the research throughout was Professor David Guest. The
part-time Research
Fellow on the project was Dr Pat Oakley. The main research assistant was
Dr Alexandra
Budjanovcanin, and there was additional support through a grant for a PhD
for Ricardo Rodrigues.
In 2010, this research received a further grant from the Department of
Health to undertake a
validation of the planning model as a five year follow up. This was
completed by April 2011.
The research brought together two existing areas of expertise in King's
College London's
Department of Management: one concerned with career theory, the other
concerned with
workforce planning. This had two related aims. The first was to establish
the best methods
available in the research literature and to utilise them to develop and
test the utility of a workforce
model to assess the future demand for and supply of pharmacists. It
revealed an increasing
shortage of pharmacists for a number of years and therefore a need to
increase the supply of
pharmacists through the education system. This was based on known factors
such as current
numbers of pharmacists and their expressed intention to reduce working
hours, the education
throughput of newly qualified pharmacists and developments in technology
together with the
estimated 5 per cent per annum growth in demand. The follow-up review and
surveys, including
data up to 2009, confirmed that over the subsequent five year period the
predictions from the first
planning model had proved to be very robust. This served as confirmation
that over the relatively
short term, careful workforce planning in this part of healthcare can be
effective.
The second aim was to develop theory and empirical research in three
related areas of research
which focussed on career orientations, career boundaries and career
regret. This has resulted in
new insights on how each of these career issues affect labour market
behaviour. We now know
more clearly how career aspirations relating to remaining within the
profession, to working part
time, to reducing working hours and to the desire for career breaks, all
affect the supply of labour.
For example, the career study revealed risks to supply resulting from the
porous boundaries
between jobs and between work and non-work and found that in 2005, 23 per
cent of pharmacists
had more than one job, 38 per cent worked part-time and 45 per cent
expected to reduce their
working hours within the next five years. These findings were used to
inform the planning model.
References to the research
1. Guest, D., Oakley, P., Clinton, M. and Budjanovcanin, A. (2006) "Free
or precarious? A
comparison of the attitudes of workers in flexible and traditional
employment contracts".
Human Resource Management Review, 16, 107-124.
2. Guest, D., Budjanovcanin, A. and Oakley, P. (2009). "Pharmacy
workforce country case
study: Great Britain". In FIP 2009 Global Pharmacy Workforce Report:
40-48.
3. Guest, D., Budjanovcanin, A. and Oakley, P. (2010) "Planning the
pharmaceutical
workforce: what pharmacists want in their careers and what they have got".
The
Pharmaceutical Journal, 281, 22 Nov., 598-600.
4. Guest, D, Budjanovcanin, A and Oakley, P. (2010) "Planning the
pharmacy workforce: Will
pharmacists stay in pharmacy?" Pharmaceutical Journal, 281, 6
Dec., 672-676.
5. Guest, D., Budjanovcanin, A., and Oakley, P. (2010) "Planning the
pharmacy workforce: Is
there a shortage of pharmacists?" Pharmaceutical Journal, 281, 13
Dec., 696-698.
6. Rodrigues, R and Guest, D. (2011) "Have careers become boundaryless?"
Human
Relations, 63:1157-1175.
Supporting Grants
Guest, D. and Oakley, P. (2010-2011) `An update of the pharmacy workforce
model', Department
of Health, (£74,937).
Guest, D. with Budjanovcanin, A. (2007-2010) `Future workforce planning
for the Pharmacy
profession: A study of issues pertaining to gender and ethnicity in
careers in Pharmacy', ESRC
Case Award with Royal Pharmaceutical Society of Great Britain,
(£63,500).
Guest, D. (2004-2005) `Study of staff working in university departments
of Pharmacy', Royal
Pharmaceutical Society of Great Britain, (£47,399).
Details of the impact
King's research changed thinking at the Department of Health and the
RPSGB, leading them to
focus on the issue of workforce planning for the first time. This
subsequently led to action to
address a shortage of pharmacists identified in the research. This action
included the
establishment of eight new Schools of Pharmacy, the generation of
sufficient numbers of
pharmacists by 2013, and changes to regulations on the hours that
community pharmacies could
open.
There was engagement with beneficiaries from the outset, because the
research in question was
commissioned by the Department of Health through the RPSGB. The academic
team placed great
importance on establishing a constructive dialogue and there was extensive
involvement of a wide
range of stakeholders in an adivisory group from research design through
to presentation of
results, with initial results communicated to the RPSGB and the Department
of Health ahead of the
resulting academic publications. The findings were presented in a detailed
report, a workforce
model and in a summarised, accessible form to the advisory group. In
addition the research was
presented in full and formally to the RPSGB and Department of Health.
King's research provided the Department of Health with a carefully
developed and tested workforce
model for pharmacy and also drew their attention to the generalisability
of this approach for other
parts of the health workforce. For relevant policy-makers in the
Department, the quality of the
analysis provided a specific benefit in that it provided a strong analytic
evidence base for policy
decisions. As the Head of Education and Training, of the Department of
Health wrote:
... real impact came from making people think about workforce at all.
Being able to show
what happens if participation rates go up or attrition in universities
goes up, for example,
was incredibly powerful. (Source A)
Specifically, the model and its findings underpinned and provided crucial
evidence in support of the
decision to open eight new Schools of Pharmacy and strengthen some
existing ones. Findings in
2004 had already identified a shortage of pharmacists that was likely to
get worse for some years
unless the supply of pharmacists improved. In addition, the study also
provided an assessment of
the risk of relying on the goodwill implied by the finding that
pharmacists typically worked an
average of four hours longer than they were formally paid to work. The
survey revealed evidence
of the strong desire to reduce work commitments, including working hours,
suggesting that this
goodwill should not be taken for granted, and further confirming the need
to increase supply of
pharmacists. Three direct changes resulted in the assessment period after
2008. (1) The
anticipated shortage of pharmacists and the strain identified on the
existing workforce was
considered sufficiently serious to lead to support for the opening and
accrediting of eight new
Schools of Pharmacy at UK universities, initially including East Anglia,
Keele, Kent Medway,
Reading and Wolverhampton as well as some expansion of provision at
existing Schools of
Pharmacy. The new schools started to operate in 2009. (2) A report from
the Centre for Workforce
Intelligence, which updated the forecasts of workforce demand and
potential supply up to 2040,
confirmed that in 2013 supply of pharmacists now broadly matches demand
(Source B). Thus, as
an impact of King's research, the significant shortfall in pharmacists had
been addressed by the
generation of additional new capacity in the new Schools. (3) King's
findings additionally confirmed
the need to change the national regulations to extend the hours that
community pharmacy services
could operate. In addition, the regulations affecting opening hours of
pharmacies were changed in
2008 following a related OFT study (Source C).
There were four significant contingent impacts of King's pharmacy
workforce research. 1. The
universities that received support and accreditation to open new Schools
of Pharmacy benefitted
by being able to introduce popular new courses in high demand from
potential students. 2. The
public at large benefitted through improved capacity and the availability
of more pharmacists to
meet the expanding demands for pharmacy services to protect and promote
the health of the
nation. 3.The RPSGB benefitted from King's research as a research sponsor
and key stakeholder
through its strengthened ability to contribute to policy decisions through
the research. 4. The
decision to increase the number of individuals entering pharmacy also
benefitted the RPSGB by
increasing its membership. The Head of Professional Development confirmed
this impact on the
RPSGB and the wider impact of the research in correspondence. She wrote:
This research programme was the RPSGB's first attempt [at modelling the
demands for
pharmacists] and the Society was able for the first time to understand the
workforce
projections under different policy assumptions. As a result the Society
now employs a
dedicated policy officer to carry forward its workforce policy programme
using the
methodology developed for this research project.
The workforce survey identified important factors concerning pharmacists'
professional
identity and the importance they place on participating in Continued
Professional
development. As a result, the Society has made this a central part of its
support for
pharmacists and underpinned the development of the Society's role for the
future.
(Source D)
This confirms the transformation of understanding, policy, educational
provision and capacity
regarding the pharmacist workforce, as well as indirect wider healthcare
impact in society, resulting
from the King's research.
Sources to corroborate the impact
A. Email from Head of Education and Training, Health Education
England/Department of
Health England and ex Director of Research for the Royal Pharmaceutical
Society of Great
Britain to Professor David Guest, 2nd June 2012. Available on
request.
B. Centre for Workforce Intelligence (CFWI) `A Strategic Review of the
Future Pharmacist
Workforce: Informing Pharmacy Student Intake'. CfWI, UK, 2013.
http://www.cfwi.org.uk/publications/a-strategic-review-of-the-future-pharmacist-workforce
C. Office of Fair Trading (OFT) `The control of entry regulations and
retail pharmacy services
in the UK. A report of an OFT market investigation'. OFT, 2003.
http://www.oft.gov.uk/shared_oft/reports/comp_policy/oft609.pdf
D. Correspondence from Head of Professional Development, Royal
Pharmaceutical Society of
Great Britain to Professor Guest, 27 September 2013.
E. Chief Scientific Officer, NHS England will corroborate the policy
impact if contacted.
F. Chief Pharmaceutical Officer, Department of Health England will
corroborate the policy
impact if contacted.